About sorafenib in castration-resistant prostate cancer.
Colloca
G
G
Checcaglini
F
F
Venturino
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D009919:Orchiectomy; D010671:Phenylurea Compounds; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D017430:Prostate-Specific Antigen